Nigeria - Multiple Indicator Cluster Survey/National Immunization Coverage Survey 2016-17, Fifth round (MICS) and NICS (third Round)

Reference ID

NGA-NBS-MICS5-NICS-2016-17-v1.1

Year

2016 - 2017

Country

Nigeria

Producer(s)

National Bureau of Statistics (NBS) - Federal Government of Nigeria

Sponsor(s)

Bill and Melinda Gates Foundation - Bill Gates - Funding partner
United Nations Children's Fund - UNICEF - Sponsor
Save One Million Lives - SOML - Funding partner
United Nations Population Fund - UNFPA - Funding partner
World Bank - W

Metadata

Documentation in PDF Download DDI Download RDF

Study website

Created on

Feb 20, 2019

Last modified

Feb 20, 2019

Page views

791421

Downloads

53644

Times took SP / Fansidar (MN16)
File: MICS5 INDIVIDUAL WOMEN MODULE

Overview

Type: Discrete
Format: numeric
Width: 2
Decimals: 0
Range: 1-99

Valid cases: 3425
Invalid: 32751

Categories

Value	Category	Cases
1		1093	31.9%
2		1186	34.6%
3		639	18.7%
4		181	5.3%
5		100	2.9%
6		48	1.4%
7		23	0.7%
8		23	0.7%
9		3	0.1%
10		13	0.4%
11		2	0.1%
12		7	0.2%
13		1	0.0%
14		6	0.2%
15		3	0.1%
16		1	0.0%
17		1	0.0%
21		1	0.0%
22		1	0.0%
30		2	0.1%
50		1	0.0%
98	DK	86	2.5%
99	Missing	4	0.1%
Sysmiss		32751

Warning: these figures indicate the number of cases found in the data file. They cannot be interpreted as summary statistics of the population of interest.

Questions and instructions

Pre question

Check MN14 for medicine taken:
Sulphadoxine Pyrimethamine /Fansidar taken. Continue with MN16.

¨

Literal question

During your pregnancy with (name), how many times did you take SP/ Fansidar in total?

Post question

Please include all that you obtained either during an antenatal care visit, during a visit to a health facility or from another source?
Sulphadoxine Pyrimethamine /Fansidar not taken. Go to MN17.

Interviewer instructions

This module is to be administered to all women with a live birth in the 2 years preceding the date of interview. Record name of last-born child from CM13 here _____________________. Use this child’s name in the following questions, where indicated.